Keyword search (4,163 papers available)

"Insomnia" Keyword-tagged Publications:

Title Authors PubMed ID
1 Perceptions et attitudes des personnes âgées souffrant d insomnie par rapport aux médicaments et aux produits de santé naturels Nguyen PV; Dang-Vu T; Forest G; Saidi L; Desmarais P; 40968485
CONCORDIA
2 Relationship Between Lumbar Multifidus Morphometry and Pain/Disability in Individuals With Chronic Nonspecific Low Back Pain After Considering Demographics, Fear-Avoidance Beliefs, Insomnia, and Spinal Degenerative Changes Pinto SM; Cheung JPY; Samartzis D; Karppinen J; Zheng YP; Pang MYC; Fortin M; Wong AYL; 40376565
SOH
3 Efficacy of cognitive behavioral therapy for insomnia and lemborexant medication for different subtypes of chronic insomnia: study protocol for a randomized controlled trial Chen SJ; Ivers H; Dang-Vu TT; Shapiro CM; Carney CE; Robillard R; Morin CM; 40346496
HKAP
4 Cognitive-behavioural therapy for insomnia mechanism of action: Exploring the homeostatic K-complex involvement Sforza M; Morin CM; Dang-Vu TT; Pomares FB; Perrault AA; Gouin JP; Bušková J; Janku K; Vgontzas A; Fernandez-Mendoza J; Bastien CH; Riemann D; Baglioni C; Carollo G; Casoni F; Zucconi M; Castronovo V; Galbiati A; Ferini-Strambi L; 39739397
SOH
5 Effect of age on hypnotics' efficacy and safety in insomnia: A systematic review and meta-analysis Patrick Viet-Quoc N; Thien Thanh DV; Philippe L; Sebastien C; Lidia S; Philippe D; 39603114
CONCORDIA
6 Trends in nighttime insomnia symptoms in Canada from 2007 to 2021 Chaput JP; Morin CM; Robillard R; Carney CE; Dang-Vu TT; Davidson JR; Tomkinson GR; Lang JJ; 39556998
HKAP
7 Delphi consensus recommendations for the management of chronic insomnia in Canada Morin CM; Khullar A; Robillard R; Desautels A; Mak MSB; Dang-Vu TT; Chow W; Habert J; Lessard S; Alima L; Ayas NT; MacFarlane J; Kendzerska T; Lee EK; Carney CE; 39481275
HKAP
8 Prevalence of insomnia and use of sleep aids among adults in Canada Morin CM; Vézina-Im LA; Chen SJ; Ivers H; Carney CE; Chaput JP; Dang-Vu TT; Davidson JR; Belleville G; Lorrain D; Horn O; Robillard R; 39369578
HKAP
9 Predicting response to stepped-care cognitive behavioral therapy for insomnia using pre-treatment heart rate variability in cancer patients Garneau J; Savard J; Dang-Vu TT; Gouin JP; 38991424
HKAP
10 Sleep spindles predict stress-related increases in sleep disturbances Dang-Vu TT; Salimi A; Boucetta S; Wenzel K; O' Byrne J; Brandewinder M; Berthomier C; Gouin JP; 25713529
PERFORM
11 High-frequency heart rate variability during worry predicts stress-related increases in sleep disturbances Gouin JP; Wenzel K; Boucetta S; O' Byrne J; Salimi A; Dang-Vu TT; 25819418
PERFORM
12 Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder Arnold V; Ancoli-Israel S; Dang-Vu TT; Mishima K; Pinner K; Malhotra M; Moline M; 38748321
HKAP
13 Methodological approach to sleep state misperception in insomnia disorder: Comparison between multiple nights of actigraphy recordings and a single night of polysomnography recording Maltezos A; Perrault AA; Walsh NA; Phillips EM; Gong K; Tarelli L; Smith D; Cross NE; Pomares FB; Gouin JP; Dang-Vu TT; 38325157
HKAP
14 Economic burden of insomnia symptoms in Canada Chaput JP; Janssen I; Sampasa-Kanyinga H; Carney CE; Dang-Vu TT; Davidson JR; Robillard R; Morin CM; 36319579
PERFORM
15 Insomnia disorder increases the risk of subjective memory decline in middle-aged and older adults: a longitudinal analysis of the Canadian Longitudinal Study on Aging Zhao JL; Cross N; Yao CW; Carrier J; Postuma RB; Gosselin N; Kakinami L; Dang-Vu TT; 35877203
PERFORM
16 Sleep disorders in patients with a neurocognitive disorder C Moderie 34916075
PERFORM
17 Insomnia symptom subtypes and manifestations of prodromal neurodegeneration: a population-based study in the CLSA Yao CW; Pelletier A; Fereshtehnejad SM; Cross N; Dang-Vu T; Postuma RB; 34314348
PERFORM
18 More than a quarter century of the most prescribed sleeping pill: Systematic review of zolpidem use by older adults. Machado FV, Louzada LL, Cross NE, Camargos EF, Dang-Vu TT, Nóbrega OT 32360985
PERFORM
19 Inactograms and objective sleep measures as means to capture subjective sleep problems in patients with a bipolar disorder. Lavin-Gonzalez P, Bourguignon C, Crescenzi O, Beaulieu S, Storch KF, Linnaranta O 32232937
PSYCHOLOGY
20 Failure of fear extinction in insomnia: An evolutionary perspective. Perogamvros L, Castelnovo A, Samson D, Dang-Vu TT 32143023
PERFORM
21 High-Frequency Heart Rate Variability Reactivity and Trait Worry Interact to Predict the Development of Sleep Disturbances in Response to a Naturalistic Stressor. MacNeil S, Deschênes SS, Caldwell W, Brouillard M, Dang-Vu TT, Gouin JP 28527014
PERFORM
22 Sleep spindles may predict response to cognitive-behavioral therapy for chronic insomnia Dang-Vu TT; Hatch B; Salimi A; Mograss M; Boucetta S; O' Byrne J; Brandewinder M; Berthomier C; Gouin JP; 29157588
PERFORM
23 Cortical Thinning and Altered Cortico-Cortical Structural Covariance of the Default Mode Network in Patients with Persistent Insomnia Symptoms. Suh S, Kim H, Dang-Vu TT, Joo E, Shin C 26414892
PERFORM
24 Association between insomnia disorder and cognitive function in middle-aged and older adults: a cross-sectional analysis of the Canadian Longitudinal Study on Aging Cross NE; Carrier J; Postuma RB; Gosselin N; Kakinami L; Thompson C; Chouchou F; Dang-Vu TT; 31089710
PERFORM

 

Title:Economic burden of insomnia symptoms in Canada
Authors:Chaput JPJanssen ISampasa-Kanyinga HCarney CEDang-Vu TTDavidson JRRobillard RMorin CM
Link:https://pubmed.ncbi.nlm.nih.gov/36319579/
DOI:10.1016/j.sleh.2022.09.010
Publication:Sleep health
Keywords:Economic costHealth care costInsomniaPublic health
PMID:36319579 Category: Date Added:2022-11-02
Dept Affiliation: PERFORM
1 Healthy Active Living and Obesity Research Group, CHEO Research Institute, Ottawa, Ontario, Canada; Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: jpchaput@cheo.on.ca.
2 School of Kinesiology and Health Studies, Queen's University, Kingston, Ontario, Canada; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
3 Healthy Active Living and Obesity Research Group, CHEO Research Institute, Ottawa, Ontario, Canada.
4 Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada.
5 Institut Universitaire de Gériatrie de Montréal and CRIUGM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, Quebec, Canada; PERFORM Centre, Center for Studies in Behavioral Neurobiology, Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, Quebec, Canada.
6 Department of Psychology, Queen's University, Kingston, Ontario, Canada.
7 The University of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada; School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.
8 School of Psychology, Laval University, Quebec City, Quebec, Canada.

Description:

Objective: To estimate health care and productivity costs associated with insomnia symptoms in Canadian adults.

Methods: Three pieces of information were needed to calculate estimates based on a prevalence-based approach: (1) the pooled relative risk estimates of health outcomes consistently associated with insomnia symptoms obtained from recent meta-analyses of prospective cohort studies; (2) the direct (health care) and indirect (lost productivity due to premature mortality) costs of these health outcomes using the Economic Burden of Illness in Canada information; and (3) the prevalence of insomnia symptoms in Canadian men (18.1%) and women (29.5%) obtained from a nationally-representative survey.

Results: The direct, indirect, and total costs of insomnia symptoms in Canada in 2021 were $1.9 billion, $12.6 million, and $1.9 billion, respectively. This value represents 1.9% of the overall burden of illness costs for 2021 in Canada. The 2 most expensive chronic diseases attributable to insomnia symptoms were type 2 diabetes ($754 million) and depression ($706 million). The main contributor to the costs for type 2 diabetes and depression was prescription drugs. A 5% decrease in insomnia symptoms (from 23.8% to 18.8%) would result in an estimated $353 million in avoided costs while a 5% increase in insomnia symptoms (from 23.8% to 28.8%) would result in an estimated $333 million in additional expenditures yearly.

Conclusions: Insomnia symptoms greatly contribute to the economic burden of illness in Canada. Reducing the prevalence of insomnia symptoms would reduce its societal burden.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University